Answers are grounded in this paper and cite their sources.
Importance Cancer survivors are individuals with a diagnosis of malignant neoplasm, either living with (ie, current cancer survivors) or free of (ie, past cancer survivors) cancer. As the prevalence of cancer survivors of reproductive age increases worldwide, assessment of pregnancy characteristics and outcomes among past cancer survivors is important. Objective To assess the temporal trends, clinical and obstetric characteristics, and maternal morbidity at delivery among current and past cancer survivors. Design, Setting, and Participants This nationwide cross-sectional study used National Inpatient Sample data for hospital deliveries from 2016 to 2023. Analyses were conducted from April to May 2026. Exposure A prior or current diagnosis of cancer at hospital delivery, with individuals classified as being a past cancer survivor, a current cancer survivor, or an individual without a cancer diagnosis. Main Outcome and Measure The primary outcome was severe maternal morbidity at delivery, assessed with multivariable generalized linear models with a Poisson distribution. Results Among 28 360 443 hospital deliveries, there were 106 740 (0.4%) hospital deliveries for past cancer survivors, 21 975 (<0.1%) for current cancer survivors, and 28 231 728 (99.5%) without a cancer diagnosis. The median (IQR) maternal age at delivery was 33 (29-36), 32 (27-36), and 29 (25-33) years among past cancer survivors, current cancer survivors, and individuals without a cancer diagnosis, respectively. During the 8-year study period, hospital deliveries for past cancer survivors increased from 30.1 to 45.6 per 10 000 hospital deliveries (average annual percentage change [AAPC] = 6.3% [95% CI, 5.1%-7.9%]), whereas hospital deliveries for current cancer survivors were unchanged (7.0 to 7.4 per 10 000 hospital deliveries; AAPC = 0.2% [95% CI, −2.8% to 3.7%]). Most hospital deliveries (57.6%) for past cancer survivors were full-term, whereas only 39.6% were full-term for current cancer survivors. Compared with the no cancer group, the severe maternal morbidity rate was higher for the past cancer survivor group (11.9 vs 6.8 per 1000 hospital deliveries; adjusted incidence rate ratio [IRR], 1.45 [95% CI, 1.37-1.53]) and for the current cancer survivor group (48.2 vs 6.8 per 1000 hospital deliveries; adjusted IRR, 3.80 [95% CI, 3.58-4.04]), including the inpatient maternal mortality rate during the hospital delivery admission (273.0 vs 7.0 per 100 000 hospital deliveries; adjusted IRR, 14.24 [95% CI, 10.87-18.66]). Conclusions and Relevance In this US cross-sectional study, the prevalence of hospital deliveries for past cancer survivors increased from 2016 to 2023, and severe maternal morbidity was increased at delivery for past and current cancer survivors. These findings support the importance of preconception evaluation for cancer survivors and early referral to tertiary care centers with multidisciplinary teams, as currently recommended by multiple organizations.
No takes yet. Share an insight, caveat, or question.
Matsuo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: